Ardelyx names new chief business and human resources officers
US cardiorenal-focussed drugmaker Ardelyx’ (Nasdaq: ARDX) announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer.
Since joining Ardelyx in March 2024, Mr Kelliher has established himself as important leader driving Ardelyx’ long-term growth and value creation strategies. In his newly expanded role as CBO, Mr Kelliher will be responsible for lifecycle and portfolio management, in addition to his previous responsibilities for business development and corporate strategy.
Mr Brady is a purpose-driven human resources executive with a proven track record of building organizations, leaders and teams in transformational life science and digital innovation technologies. He will be responsible for HR strategy and processes related to building and retaining a high performing team that can effectively support Ardelyx’ continued growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze